Cullinan Therapeutics, Inc.

Cullinan Therapeutics, Inc.

CGEM·NASDAQ

$15.21

-0.85%
HealthcareMedical - Pharmaceuticals

Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.

At a Glance

Live Snapshot
Market Cap$934.78M
EPS-3.7200
P/E Ratio-4.09
Earnings Date08/06/2026

cgem

Stock Based Compensation

Last Annual Value

36.04M

3-Year CAGR

9%

5-Year CAGR

%

10-Year CAGR

%

Cullinan Therapeutics, Inc.

Cullinan Therapeutics, Inc. Competitors Analysis of Stock Based Compensation

CGEM · NASDAQ
CompanyStock Based Compensation
CAGR 3Y
CAGR 5Y
CAGR 10Y
36.04M
5.8%8.1%N/A 
15.00M
3.6%1.5%N/A
CBLL logo
CeriBell, Inc.
NASDAQ:CBLL
12.22M
65.9%N/AN/A
EHAB logo
Enhabit, Inc.
NYSE:EHAB
16.60M
23.1%35.8%N/A
29.61M
31.2%13.0%7.9%
29.88M
20.1%47.5%N/A
19.93M
N/A14.9%N/A
8.19M
-11.1%N/A-4.9%
Cullinan Therapeutics, Inc.

Cullinan Therapeutics, Inc. Fair Value Envelope

CGEM · NASDAQ

Our analysis suggests that CGEM has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $15.21, this represents a potential HIDDEN relative to our calculated worth for Cullinan Therapeutics, Inc..

Intrinsic Value
Current Price: $15.21